News | Atrial Fibrillation | September 13, 2021

Ablation and Biventricular Pacing Boosts Survival in Selected Atrial Fibrillation Patients in APAF-CRT Trial

AV junction ablation and CRT reduced the secondary endpoint of the combined risks of death from any cause or hospitalization for heart failure by 60%

Ablation and Biventricular Pacing Boosts Survival in Selected Atrial Fibrillation Patients in APAF-CRT Trial. #ESC #ESCcongress

September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate control in reducing mortality in severely symptomatic permanent atrial fibrillation (AF) patients with a narrow QRS, according to the late-breaking APAF-CRT trial presented in a Hot Line session at the European Society of Cardiology (ESC) Congress 2021 and published in the European Heart Journal.[1,2]

Previous research has shown that in patients with AF, atrioventricular (AV) junction ablation and right ventricular pacing improved symptoms, quality of life, and cardiac function by slowing and regularizing the ventricular rate. However, the therapy failed to reduce mortality.[3] The authors of the current trial previously demonstrated that biventricular pacing with CRT may counteract the adverse effects of non-physiological right ventricular pacing in AF patients.[4]

“We hypothesize that the observed benefit was due to the combination of the strict rate control and rate regularization achieved by AV junction ablation, together with biventricular pacing which counteracted the adverse effects of right ventricular pacing. The improvement in survival shown by the APAF-CRT trial supports ablation plus CRT as a first line therapy in patients with permanent AF, narrow QRS and previous hospitalization for heart failure,” explained principal investigator Professor Michele Brignole of the IRCCS Istituto Auxologico Italiano, San Luca Hospital, Milan.

APAF-CRT was a two-phase trial in patients with severely symptomatic permanent AF and a narrow QRS. The first phase, focused on morbidity, showed that AV junction ablation and CRT reduced hospitalization due to heart failure and improved heart failure symptoms compared with pharmacological rate control at two years of follow-up.[5]

Results of the second phase, focused on mortality, were presented at ESC 2021. In a larger population with a longer follow-up, the trial tested the hypothesis that AV junction ablation and biventricular pacing is superior to pharmacological rate control therapy in reducing all-cause mortality.

This was a multi-center, international, prospective, randomized, parallel, open-label trial with a blinded outcome. Patients were enrolled with the following inclusion criteria: severely symptomatic permanent AF (over six months) considered unsuitable for AF ablation or in whom AF ablation had failed; narrow QRS (110 ms or below); and at least one hospitalization for heart failure in the previous year.

Patients were randomly assigned in a 1:1 fashion to AV junction ablation and biventricular pacing (ablation + CRT arm) or optimal pharmacological rate control therapy (drug arm). Patients in both arms could additionally be given a defibrillator at the discretion of their physician according to ESC guidelines.6

A total of 133 patients were randomized. The mean age was 73 years and 62 (47%) were women. The trial was stopped for efficacy at the interim analysis after a median of 29 months of follow-up per patient.

The primary endpoint of death from any cause occurred in seven patients (11%) in the ablation+CRT arm and in 20 patients (29%) in the drug arm (hazard ratio 0.26; 95% confidence interval [CI] 0.10–0.65; p=0.004). The estimated death rates at four years were 14% and 41% in the ablation+CRT and drug arms, respectively. At four years, the relative and absolute risk reductions were 74% and 27%, respectively, and the number needed to treat was 3.[7]

Moreover, AV junction ablation and CRT reduced the secondary endpoint of the combined risks of death from any cause or hospitalization for heart failure by 60% (95% CI 0.22–0.73; p=0.002).

The APAF-CRT trial is an investigator-initiated independent clinical trial, sponsored by a non-profit organization named Centro Prevenzione Malattie Cardiorespiratorie “Nuccia e Vittore Corbella”, Rapallo, Italy which received an unrestricted research grant from The Boston Scientific Investigator Sponsored Research (ISR) Committee, Boston Scientific, St. Paul, Minn. Boston did not influence the trial design, data collection, analysis, or the decision to publish.

Find more ESC Hot Line late-breaking study news

 

References:

1. APAF-CRT: AV junction ablation and CRT in patients with permanent atrial fibrillation and narrow QRS. Session presentation at ESC 2021.

2. Brignole M et al. Benefit of AV junction ablation and cardiac resynchronization therapy on mortality among patients with permanent atrial fibrillation and narrow QRS. The APAF-CRT Long-Term Outcome Randomized Clinical Trial. Eur Heart J. Link will go live on publication: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehab569.

3. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med. 2001;344:1043–1051.

4. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32:2420–2429.

5. Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018;39:3999–4008.

6. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2013;34:2281–2329.

 

Related Content

The Acutus Medical AcQBlate Force sensing ablation catheter.

The Acutus Medical AcQBlate Force sensing ablation catheter.

News | Ablation Systems | April 05, 2021
April 5, 2021 — Acutus Medical today announced initial U.S.
The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...